top of page

Antibody oligonucleotide conjugates as an RNA strategy with the CEO of Avidity Biosciences

  • blonca9
  • Nov 1, 2023
  • 1 min read

Sarah Boyce explains the rationale for using AOCs against muscle disorders like myotonic dystrophy type 1 and DMD, and describes the clinical data Avidity has collected so far.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page